BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) CEO James Passin tells Proactive's Stephen Gunnion that a deal granting it exclusive US marketing and distribution rights for two products that treat cervical lesions, and right of first refusal on two other fertility and menopause products will help position BioVaxys as a leading player in women's healthcare in the US.
The company has executed a binding term sheet with Barcelona-based Procare Health Iberia, granting it exclusive US marketing and distribution rights for Paplicocare, used to prevent and treat HPV-dependent cervical lesions, and Immunocaps, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.
#ProactiveInvestors #BioVaxysTechnology #ProcareHealthIberia #Papilocare #Immunocaps #HPV